Cambridge Cognition Holdings (COG) AI Stock Analysis

• Market Cap: £17.47M
• Dividend Yield: N/A
• Average Volume (3M): 33.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: -30.77%
• EPS Growth: -6.97%
• Country: UK
• Employees: 119
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.02
• Shares Outstanding: 46,040,413
• 10 Day Avg. Volume: 39,076
• 30 Day Avg. Volume: 33,983
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £32.00
• Price Target Upside: -15.79% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: 32.00p ▼(-15.79% Downside)

The overall stock score of 46 reflects significant financial and technical challenges. The company's declining revenue and negative profitability metrics are major concerns, compounded by bearish technical indicators and a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Cambridge Cognition Holdings Business Overview & Revenue Model

Company Description

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online trial recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I–IV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and NeuroVocalix for an automated administration and scoring of well-validated verbal cognitive assessments?on a secure platform. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.

How the Company Makes Money

Cambridge Cognition generates revenue through several key streams. The primary source is the sale of its cognitive assessment software, which includes licensing agreements with pharmaceutical companies and research institutions that utilize its products for clinical trials and studies. Additionally, the company earns revenue from providing services such as consultancy and data analytics related to cognitive assessments. Cambridge Cognition also benefits from strategic partnerships with industry leaders and academic institutions that enhance its product offerings and expand its market reach. These collaborations often lead to joint research initiatives and increased visibility in the healthcare sector, contributing to sustained earnings growth.

Cambridge Cognition Holdings Financial Statement Overview

Summary

Cambridge Cognition Holdings faces operational and financial challenges, with declining revenue and negative profitability metrics. Despite improvements in equity levels, high leverage and negative cash flows pose liquidity risks.

Income Statement

The company has shown a fluctuating revenue trajectory, with revenue decreasing from £13.52M in 2023 to £10.34M in 2024. Despite experiencing growth in previous years, the recent decline poses a concern. Gross profit margins remain relatively strong at 81.1% in 2024, but negative EBIT and net profit margins indicate ongoing operational challenges, with EBIT margin at -11.3% and net profit margin at -17.3% in 2024.

Balance Sheet

Cambridge Cognition Holdings has improved its equity from a negative position in 2019 to a positive £3.36M in 2024, indicating strengthening financial stability. However, a high debt-to-equity ratio of 0.57 suggests moderate leverage. The equity ratio stands at 25.8%, reflecting a moderate level of equity financing relative to total assets.

Cash Flow

The cash flow situation reveals significant challenges, with a negative operating cash flow of £-3.09M in 2024 and free cash flow deteriorating from £1.49M in 2022 to £-3.09M in 2024. This decline in free cash flow growth rate indicates potential liquidity issues. Operating cash flow to net income ratio is negative due to losses, highlighting the need for strategic cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.34M	13.52M	12.61M	10.09M	6.74M
Gross Profit	8.39M	10.80M	9.32M	8.08M	5.42M
EBITDA	-542.00K	-2.62M	-514.00K	294.00K	-502.00K
Net Income	-1.78M	-3.51M	-409.00K	450.00K	-438.00K
Balance Sheet
Total Assets	13.03M	14.23M	15.11M	12.54M	6.26M
Cash, Cash Equivalents and Short-Term Investments	1.30M	3.23M	8.32M	6.81M	3.05M
Total Debt	1.91M	2.56M	18.00K	18.00K	98.00K
Total Liabilities	9.67M	12.95M	15.01M	11.91M	6.21M
Stockholders Equity	3.36M	1.28M	95.00K	632.00K	57.00K
Cash Flow
Free Cash Flow	-3.09M	-5.00M	1.49M	3.88M	972.00K
Operating Cash Flow	-3.08M	-4.97M	1.68M	3.93M	1.01M
Investing Cash Flow	50.00K	-3.02M	-189.00K	-105.00K	-42.00K
Financing Cash Flow	1.13M	2.88M	-132.00K	-86.00K	1.17M

Cambridge Cognition Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:COG, the sentiment is Positive. The current price of 38 is above the 20-day moving average (MA) of 32.44, above the 50-day MA of 30.40, and above the 200-day MA of 36.01, indicating a bullish trend. The MACD of 2.37 indicates Negative momentum. The RSI at 88.52 is Negative, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:COG.

Cambridge Cognition Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	64 Neutral	10.66M	-4.94	-21.14%	―	7.27%	39.64%
PRM	47 Neutral	9.92M	-2.92	52.27%	―	-2.80%	-38.55%
COG	46 Neutral	£17.47M	―	-68.57%	―	-30.77%	-6.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cambridge Cognition Holdings Corporate Events

Cambridge Cognition Launches AI-Driven Solution to Enhance Clinical Trial Integrity

Cambridge Cognition Holdings has launched a proprietary speaker identification solution aimed at preventing duplicate participant enrolment in clinical trials, a significant issue affecting data integrity and study validity. This solution, which is part of the company’s AI voice-enabled data quality management tools, has already secured initial commercial deals and is expected to be deployed by a major pharmaceutical client in Q4 2025, reflecting the company’s strategic commitment to enhancing reliability and efficiency in clinical research.

Cambridge Cognition Sees Strong Sales Growth Amid Revenue Challenges

Cambridge Cognition Holdings reported significant growth in new sales orders and an increased order book for the first half of 2025, despite a decline in revenue compared to the previous year. The company is optimistic about future revenue growth and profitability, driven by a strong pipeline of opportunities and strategic expansion into healthcare and consumer health markets. However, the cancellation of two clinical studies will impact cash generation in the second half of the year. The company remains focused on building its order book and expanding its presence in professional healthcare and consumer health markets.

Cambridge Cognition Successfully Concludes AGM with All Resolutions Passed

Cambridge Cognition Holdings plc announced the successful conclusion of its Annual General Meeting, where all resolutions were passed, including the approval of the 2024 Report and Accounts, directors’ remuneration, and the re-election of several directors. The meeting’s outcomes reflect strong shareholder support and position the company to continue its strategic initiatives in the digital health sector, enhancing its market presence and operational capabilities.

Cambridge Cognition’s Investment Achieves Positive Trial Results for Schizophrenia Treatment

Cambridge Cognition Holdings announced that its investment, Monument Therapeutics, has achieved positive Phase I clinical trial results for MT1988, a novel treatment for cognitive impairment associated with schizophrenia. This milestone demonstrates favorable safety and tolerability profiles, supporting the advancement to Phase II development. The success of MT1988, which addresses a critical unmet need in schizophrenia treatment, is expected to enhance the company’s value through potential future royalties and reinforces its position in the brain health industry.

Cambridge Cognition Releases 2024 Annual Report and AGM Notice

Cambridge Cognition Holdings PLC has published its 2024 Annual Report and Accounts along with the Notice of the Annual General Meeting (AGM) on its website. The AGM is scheduled for June 27, 2025, at the company’s registered office in Cambridge. This announcement underscores the company’s commitment to transparency and engagement with its stakeholders, as it continues to build a strong global brand in the brain health software industry.